How Ruxolitinib Will Change the Future of Vitiligo Treatment


Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.